UNSPSC 51334507: Loxapine hydrochloride

This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C18H18ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 376MYL4MAL, chemically known as 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine monohydrochloride but more generally known as loxapine hydrochloride, which bears US NIH Compound Identifier 71400. European Medicines Agency schedules Loxapine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22686.

UNSPSC 51334507 Loxapine hydrochloride is a Commodity code. Recent state and local solicitations tagged with this code show little actual alignment with the code's nominal pharmaceutical scope. The opportunities instead reflect broader pharmaceutical procurement activity—generic multi-source pharmaceuticals and OTC products through cooperative purchasing; naloxone and drug deactivation systems through county health procurement; and exploratory market inquiry around direct-to-manufacturer prescription programs—rather than procurement specific to loxapine hydrochloride as an antipsychotic agent. State and local issuers using this taxonomy range from individual counties and state health agencies to multistate cooperative purchasing alliances, reflecting the fragmented nature of pharmaceutical procurement across jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems—1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the county community health building. The Texas Health and Human Services Commission issued an RFI (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs as a preliminary market intelligence step before formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness scheduled for July 1, 2026 and vendor awards conditioned on availability in the marketplace by May 15, 2026. The code shows active procurement volume but limited specificity to loxapine hydrochloride itself, signaling that this commodity classification may be a tagging artifact rather than a driver of targeted sourcing under the code.